Recon: Novo to finalize its $16.5B Catalent acquisition; FDA approves Neurocrine’s CAH treatment
ReconJason Scott
Approval/marketing authorizationBiologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited StatesUS Food and Drug Administration (FDA)